HanchorBio announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HCB303. Developed using HanchorBio’s proprietary FBDB™ platform, HCB303 is the Company’s second trispecific immunotherapy program to reach clinical development.

HanchorBio announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.